Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

Mayo Clinic

Status: Completed

Conditions: Hypercholesterolemia

Treatments: Drug: atorvastatin

Study type: Observational

Funder types: Other

Identifiers

NCT01222182

10-000986

Details and patient eligibility

About

A group of ~ 225 patients were switched from atorvastatin to an equivalent statin either by their physicians usual management or by an collaborative pharmacist coordinated process. We will compare the results of pharmacist process to the standard medical practice to find potentially which process is more effective, safer and efficient. We are surveying a total of 35 physicians, 12 using the pharmacist coordinated process and 23 not, comparing their satisfaction of the 2 processes.

Full description

This study is a retrospective analysis of patients converted from atorvastatin to another equivalent statin. It is observational because the patients were all on atorvastatin, had been informed by their prescription drug plan that it would not be covered, and that if agreed they would be changed to an equivalent that is covered by their plan. The patients were either converted with the help of pharmacist by collaborative practice agreement (CPA)or upon contacting their physician requesting a different medication. We are comparing the percentage first converted to the equivalent dose in each group and whether patients continued to be at hyperlipidemia treatment goal after the interchange.

Enrollment: 260 patients

Sex: All

Ages: 25+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

225 insured eligible subjects, 35 PCIM physicians

Trial design

260 participants in 1 patient group

Eligible plan beneficiaries on atorvastatin

Description:

A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.

Treatment:

Drug: atorvastatin